Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Stergiou Angelos M., holds the title of President and CEO at SELLAS Life Sciences Group, Inc..
On 2026-11-18, the insider transacted 26,606 shares.The shares were transacted at a weighted average price of $19.18 per share, resulting in a total market-relevant value of $510K.
Stergiou Angelos M. (President and CEO) sold $510K of $SLS
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.